Nifuroxazide prompts antitumor immune response of TCL-loaded DC in mice with orthotopically-implanted hepatocarcinoma

Zhao,Tiesuo; Jia,Huijie; Cheng,Qian; Xiao,Yali; Li,Minming; Ren,Wenjing; Li,Chen; Feng,Yuchen; Feng,Zhiwei; Wang,Hui; Zheng,Junnian

doi:10.3892/or.2017.5629

Nifuroxazide prompts antitumor immune response of TCL-loaded DC in mice with orthotopically-implanted hepatocarcinoma

Authors:
- Tiesuo Zhao
- Huijie Jia
- Qian Cheng
- Yali Xiao
- Minming Li
- Wenjing Ren
- Chen Li
- Yuchen Feng
- Zhiwei Feng
- Hui Wang
- Junnian Zheng
View Affiliations

Affiliations: Department of Immunology, Xinxiang Medical University, Xinxiang, Henan 453003, P.R. China, Department of Pathology, Xinxiang Medical University, Xinxiang, Henan 453003, P.R. China, Jiangsu Key Laboratory of Biological Cancer Therapy, Xuzhou Medical College, Xuzhou, Jiangsu 221002, P.R. China, Department of Dermatology, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan 453003, P.R. China, Research Center for Immunology, School of Basic Medical Sciences, Xinxiang Medical University, Xinxiang, Henan 453003, P.R. China
Published online on: May 5, 2017 https://doi.org/10.3892/or.2017.5629
Pages: 3405-3414

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Hepatocellular carcinoma (HCC) is a highly aggressive malignancy with a poor prognosis and high mortality. At present, vaccination with tumor cell lysate (TCL) loaded dendritic cells (DC) has been shown to be an effective therapy against HCC. However, the ability of promoting the specific T cell immune response is rather weak, influencing the antitumor response. Thus, it is necessary to find a strategy to improve the antitumor effect of TCL-loaded DC. Activation of signal transducer and activator of transcription 3 (STAT3) significantly inhibits antitumor immune response and DC maturity. Nifuroxazide, an antidiarrheal agent, has been proved to directly inhibit STAT3 activation. Thus, we investigated whether nifuroxazide could improve the antitumor immune response in mice vaccinated with TCL-loaded DC. The study provides the theoretical and experimental basis for developing an effective adjuvant for DC vaccine to treat HCC. Our results showed that the administration of nifuroxazide and DC-loaded TCL could significantly improve the survival rate, inhibit the tumor growth, and prompt the antitumor immune responses in mice with orthotopically implanted hepatocarcinomas, thus, possibly providing a new combination strategy to treat HCC.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	Llovet JM: Treatment of hepatocellular carcinoma. Curr Treat Options Gastroenterol. 7:431–441. 2004. View Article : Google Scholar : PubMed/NCBI
3	Bruix J, Reig M and Sherman M: Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology. 150:835–853. 2016. View Article : Google Scholar : PubMed/NCBI
4	Zhao F, Korangy F and Greten TF: Cellular immune suppressor mechanisms in patients with hepatocellular carcinoma. Dig Dis. 30:477–482. 2012. View Article : Google Scholar : PubMed/NCBI
5	Harding JJ, El Dika I and Abou-Alfa GK: Immunotherapy in hepatocellular carcinoma: Primed to make a difference? Cancer. 122:367–377. 2016. View Article : Google Scholar : PubMed/NCBI
6	Steinman RM and Cohn ZA: Pillars Article: Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J. Exp. Med.1973. 137: 1142–1162. J Immunol. 178:5–25. 2007.PubMed/NCBI
7	Sun K, Wang L and Zhang Y: Dendritic cell as therapeutic vaccines against tumors and its role in therapy for hepatocellular carcinoma. Cell Mol Immunol. 3:197–203. 2006.PubMed/NCBI
8	Ge C, Xing Y, Wang Q, Xiao W, Lu Y, Hu X, Gao Z, Xu M, Ma Y, Cao R, et al: Improved efficacy of therapeutic vaccination with dendritic cells pulsed with tumor cell lysate against hepatocellular carcinoma by introduction of 2 tandem repeats of microbial HSP70 peptide epitope 407–426 and OK-432. Int Immunopharmacol. 11:2200–2207. 2011. View Article : Google Scholar : PubMed/NCBI
9	Lee WC, Wang HC, Hung CF, Huang PF, Lia CR and Chen MF: Vaccination of advanced hepatocellular carcinoma patients with tumor lysate-pulsed dendritic cells: A clinical trial. J Immunother. 28:496–504. 2005. View Article : Google Scholar : PubMed/NCBI
10	Lee JH, Lee Y, Lee M, Heo MK, Song JS, Kim KH, Lee H, Yi NJ, Lee KW, Suh KS, et al: A phase I/IIa study of adjuvant immunotherapy with tumour antigen-pulsed dendritic cells in patients with hepatocellular carcinoma. Br J Cancer. 113:1666–1676. 2015. View Article : Google Scholar : PubMed/NCBI
11	Sun X, Zhang J, Wang L and Tian Z: Growth inhibition of human hepatocellular carcinoma cells by blocking STAT3 activation with decoy-ODN. Cancer Lett. 262:201–213. 2008. View Article : Google Scholar : PubMed/NCBI
12	Sui Q, Zhang J, Sun X, Zhang C, Han Q and Tian Z: NK cells are the crucial antitumor mediators when STAT3-mediated immunosuppression is blocked in hepatocellular carcinoma. J Immunol. 193:2016–2023. 2014. View Article : Google Scholar : PubMed/NCBI
13	Murone M, Chessex A Vaslin, Attinger A, Ramachandra R, Shetty SJ, Daginakatte G, Sengupta S, Marappan S, Dhodheri S, Rigotti S, et al: Debio 0617B inhibits growth of STAT3-driven solid tumors through combined inhibition of JAK, SRC, and class III/V receptor tyrosine kinases. Mol Cancer Ther. 15:2334–2343. 2016. View Article : Google Scholar : PubMed/NCBI
14	Hillmer EJ, Zhang H, Li HS and Watowich SS: STAT3 signaling in immunity. Cytokine Growth Factor Rev. 31:1–15. 2016. View Article : Google Scholar : PubMed/NCBI
15	Yu H, Kortylewski M and Pardoll D: Crosstalk between cancer and immune cells: Role of STAT3 in the tumour microenvironment. Nat Rev Immunol. 7:41–51. 2007. View Article : Google Scholar : PubMed/NCBI
16	Nelson EA, Walker SR, Kepich A, Gashin LB, Hideshima T, Ikeda H, Chauhan D, Anderson KC and Frank DA: Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3. Blood. 112:5095–5102. 2008. View Article : Google Scholar : PubMed/NCBI
17	Yang F, Hu M, Lei Q, Xia Y, Zhu Y, Song X, Li Y, Jie H, Liu C, Xiong Y, et al: Nifuroxazide induces apoptosis and impairs pulmonary metastasis in breast cancer model. Cell Death Dis. 6:e17012015. View Article : Google Scholar : PubMed/NCBI
18	Chang WT, Chen HM, Yin SY, Chen YH, Wen CC, Wei WC, Lai P, Wang CH and Yang NS: Specific Dioscorea phytoextracts enhance potency of TCL-loaded DC-based cancer vaccines. Evid Based Complement Alternat Med. 2013:9320402013. View Article : Google Scholar : PubMed/NCBI
19	Yin SY, Wang CY and Yang NS: Interleukin-4 enhances trafficking and functional activities of GM-CSF-stimulated mouse myeloid-derived dendritic cells at late differentiation stage. Exp Cell Res. 317:2210–2221. 2011. View Article : Google Scholar : PubMed/NCBI
20	Nefedova Y, Cheng P, Gilkes D, Blaskovich M, Beg AA, Sebti SM and Gabrilovich DI: Activation of dendritic cells via inhibition of Jak2/STAT3 signaling. J Immunol. 175:4338–4346. 2005. View Article : Google Scholar : PubMed/NCBI
21	Yang JD, Nakamura I and Roberts LR: The tumor microenvironment in hepatocellular carcinoma: Current status and therapeutic targets. Semin Cancer Biol. 21:35–43. 2011. View Article : Google Scholar : PubMed/NCBI
22	Kalinski P: Dendritic cells in immunotherapy of established cancer: Roles of signals 1, 2, 3 and 4. Curr Opin Investig Drugs. 10:526–535. 2009.PubMed/NCBI
23	Wang T, Niu G, Kortylewski M, Burdelya L, Shain K, Zhang S, Bhattacharya R, Gabrilovich D, Heller R, Coppola D, et al: Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med. 10:48–54. 2004. View Article : Google Scholar : PubMed/NCBI
24	Cacalano NA: Regulation of natural killer cell function by STAT3. Front Immunol. 7:1282016. View Article : Google Scholar : PubMed/NCBI
25	Hollander L, Guo X, Velazquez H, Chang J, Safirstein R, Kluger H, Cha C and Desir GV: Renalase expression by melanoma and tumor-associated macrophages promotes tumor growth through a STAT3-mediated mechanism. Cancer Res. 76:3884–3894. 2016. View Article : Google Scholar : PubMed/NCBI
26	Yue C, Shen S, Deng J, Priceman SJ, Li W, Huang A and Yu H: STAT3 in CD8⁺ T cells inhibits their tumor accumulation by downregulating CXCR3/CXCL10 axis. Cancer Immunol Res. 3:864–870. 2015. View Article : Google Scholar : PubMed/NCBI
27	Ghoshal S, Fuchs BC and Tanabe KK: STAT3 is a key transcriptional regulator of cancer stem cell marker CD133 in HCC. Hepatobiliary Surg Nutr. 5:201–203. 2016. View Article : Google Scholar : PubMed/NCBI
28	Zheng X, Xu M, Yao B, Wang C, Jia Y and Liu Q: IL-6/STAT3 axis initiated CAFs via up-regulating TIMP-1 which was attenuated by acetylation of STAT3 induced by PCAF in HCC microenvironment. Cell Signal. 28:1314–1324. 2016. View Article : Google Scholar : PubMed/NCBI
29	Tang Q, Jiang J and Liu J: CCR5 blockade suppresses melanoma development through inhibition of IL-6-Stat3 pathway via upregulation of SOCS3. Inflammation. 38:2049–2056. 2015. View Article : Google Scholar : PubMed/NCBI
30	Delirezh N, Moazzeni SM, Shokri F, Shokrgozar MA, Atri M and Kokhaei P: Autologous dendritic cells loaded with apoptotic tumor cells induce T cell-mediated immune responses against breast cancer in vitro. Cell Immunol. 257:23–31. 2009. View Article : Google Scholar : PubMed/NCBI
31	Yang DH, Park JS, Jin CJ, Kang HK, Nam JH, Rhee JH, Kim YK, Chung SY, Choi SJ, Kim HJ, et al: The dysfunction and abnormal signaling pathway of dendritic cells loaded by tumor antigen can be overcome by neutralizing VEGF in multiple myeloma. Leuk Res. 33:665–670. 2009. View Article : Google Scholar : PubMed/NCBI
32	Jia H, Li Y, Zhao T, Li X, Hu J, Yin D, Guo B, Kopecko DJ, Zhao X, Zhang L, et al: Antitumor effects of Stat3-siRNA and endostatin combined therapies, delivered by attenuated Salmonella, on orthotopically implanted hepatocarcinoma. Cancer Immunol Immunother. 61:1977–1987. 2012. View Article : Google Scholar : PubMed/NCBI
33	McMichael EL, Jaime-Ramirez AC, Guenterberg KD, Luedke E, Atwal LS, Campbell AR, Hu Z, Tatum AS, Kondadasula SV, Mo X, et al: IL-21 enhances natural killer cell response to cetuximab-coated pancreatic tumor cells. Clin Cancer Res. 23:489–502. 2017. View Article : Google Scholar : PubMed/NCBI
34	Iraolagoitia XL, Spallanzani RG, Torres NI, Araya RE, Ziblat A, Domaica CI, Sierra JM, Nuñez SY, Secchiari F, Gajewski TF, et al: NK cells restrain spontaneous antitumor CD8⁺ T cell priming through PD-1/PD-L1 interactions with dendritic cells. J Immunol. 197:953–961. 2016. View Article : Google Scholar : PubMed/NCBI
35	Kozlowska AK, Tseng HC, Kaur K, Topchyan P, Inagaki A, Bui VT, Kasahara N, Cacalano N and Jewett A: Resistance to cytotoxicity and sustained release of interleukin-6 and interleukin-8 in the presence of decreased interferon-γ after differentiation of glioblastoma by human natural killer cells. Cancer Immunol Immunother. 65:1085–1097. 2016. View Article : Google Scholar : PubMed/NCBI
36	Xia Y, Song X, Li D, Ye T, Xu Y, Lin H, Meng N, Li G, Deng S, Zhang S, et al: YLT192, a novel, orally active bioavailable inhibitor of VEGFR2 signaling with potent antiangiogenic activity and antitumor efficacy in preclinical models. Sci Rep. 4:60312014. View Article : Google Scholar : PubMed/NCBI
37	Ferrara N: VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer. 2:795–803. 2002. View Article : Google Scholar : PubMed/NCBI
38	Dong W, Xian Y, Yuan W, Huifeng Z, Tao W, Zhiqiang L, Shan F, Ya F, Hongli W, Jinghuan W, et al: Catalpol stimulates VEGF production via the JAK2/STAT3 pathway to improve angiogenesis in rats' stroke model. J Ethnopharmacol. 191:169–179. 2016. View Article : Google Scholar : PubMed/NCBI
39	Alvarez JV, Febbo PG, Ramaswamy S, Loda M, Richardson A and Frank DA: Identification of a genetic signature of activated signal transducer and activator of transcription 3 in human tumors. Cancer Res. 65:5054–5062. 2005. View Article : Google Scholar : PubMed/NCBI
40	Hsieh FC, Cheng G and Lin J: Evaluation of potential Stat3-regulated genes in human breast cancer. Biochem Biophys Res Commun. 335:292–299. 2005. View Article : Google Scholar : PubMed/NCBI
41	Miklossy G, Hilliard TS and Turkson J: Therapeutic modulators of STAT signalling for human diseases. Nat Rev Drug Discov. 12:611–629. 2013. View Article : Google Scholar : PubMed/NCBI
42	Walker SR, Xiang M and Frank DA: Distinct roles of STAT3 and STAT5 in the pathogenesis and targeted therapy of breast cancer. Mol Cell Endocrinol. 382:616–621. 2014. View Article : Google Scholar : PubMed/NCBI
43	Cheung TH, Chung TK, Lo KW, Yu MY, Krajewski S, Reed JC and Wong YF: Apotosis-related proteins in cervical intraepithelial neoplasia and squamous cell carcinoma of the cervix. Gynecol Oncol. 86:14–18. 2002. View Article : Google Scholar : PubMed/NCBI
44	Hunter AM, LaCasse EC and Korneluk RG: The inhibitors of apoptosis (IAPs) as cancer targets. Apoptosis. 12:1543–1568. 2007. View Article : Google Scholar : PubMed/NCBI